Vornorexant - 10mM in DMSO , CAS No.1517965-94-4
In stock
SKU
V656803
Vornorexant (ORN-0829; TS-142) is a potent dual OX1R and OX2R antagonist with IC 50 values of 1.05 nM and 1.27 nM, respectively. Vornorexant exhibits potent sleep-promoting effects? in vivo and can be used for insomnia research research
In Vivo
Vornorexant (oral administration; 1-10 mg/kg) exhibits potent sleep-promoting effects at a po. dose of 1 mg/kg in a rat polysomnogram study. It results in a dose-dependent increase in the percentage of total sleep . Vornorexant exhibits optimal PK properties with a rapid T max and short half-lives in rats and dogs. The T 1/2 is 0.238 hours and 1.16 hours, respectively in rat and dog . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Rat Dosage: 1, 3, 10 mg/kg Administration: Oral administration to rats prior to turning the light off (start of the active phase); 1-10 mg/kg Result: Possessed promising sleep-inducing and sleep-promoting effects.
IC50& Target:OX 2 Receptor
More Information
| CAS | 1517965-94-4 |
|---|---|
| Concentration | 10mM in DMSO |
| Specifications & Purity | 10mM in DMSO |
| Storage | Store at -80°C |
| Shipped In | Dry ice packs + Cold packs |
| Product Description | Vornorexant (ORN-0829; TS-142) is a potent dual OX1R and OX2R antagonist with IC 50 values of 1.05 nM and 1.27 nM, respectively. Vornorexant exhibits potent sleep-promoting effects? in vivo and can be used for insomnia research research In Vivo Vornorexant (oral administration; 1-10 mg/kg) exhibits potent sleep-promoting effects at a po. dose of 1 mg/kg in a rat polysomnogram study. It results in a dose-dependent increase in the percentage of total sleep . Vornorexant exhibits optimal PK properties with a rapid T max and short half-lives in rats and dogs. The T 1/2 is 0.238 hours and 1.16 hours, respectively in rat and dog . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Rat Dosage: 1, 3, 10 mg/kg Administration: Oral administration to rats prior to turning the light off (start of the active phase); 1-10 mg/kg Result: Possessed promising sleep-inducing and sleep-promoting effects. IC50& Target:OX 2 Receptor |
Reviews
Customer Reviews
Remind me later